Human ADAMTS2/ADAM-TS2/ADAMTS-2 ORF/cDNA clone-Adenovirus plasmid (NM_014244)

Cat. No.: pGMAD000269
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human ADAMTS2/ADAM-TS2/ADAMTS-2 adenoviral expression plasmid for ADAMTS2 adenovirus packaging, ADAMTS2 adenovirus.

Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to ADAMTS2/ADAM-TS2 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAD000269
Gene Name ADAMTS2
Accession Number NM_014244
Gene ID 9509
Species Human
Product Type Adenovirus plasmid (overexpression)
Insert Length 3636 bp
Gene Alias ADAM-TS2,ADAMTS-2,ADAMTS-3,EDSDERMS,NPI,PC I-NP,PCI-NP,PCINP,PCPNI,PNPI
Fluorescent Reporter Null
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGATCCGCCGGCGGGAGCCGCTCGCCGCCTGCTCTGCCCCGCGCTGCTGCTGCTGCTGCTGCTGCTGCCGCCGCCGCTCCTGCCGCCGCCGCCGCCGCCCGCGAACGCCAGGCTCGCCGCCGCCGCCGACCCCCCAGGCGGGCCCCTGGGGCACGGAGCGGAGCGCATCCTGGCGGTGCCCGTGCGCACTGACGCCCAGGGCCGCTTGGTGTCCCACGTGGTGTCGGCAGCTACGTCCAGAGCAGGGGTACGAGCCCGCAGGGCCGCCCCGGTCCGGACCCCGAGCTTCCCCGGAGGCAACGAGGAGGAGCCTGGCAGTCACCTCTTCTACAATGTCACGGTCTTTGGCCGAGACCTGCACCTGCGGCTGCGGCCCAACGCCCGCCTCGTGGCGCCCGGGGCCACTATGGAGTGGCAGGGCGAGAAGGGCACCACCCGCGTGGAGCCCCTGCTCGGGAGCTGTCTCTACGTCGGAGACGTGGCCGGCCTAGCCGAAGCCTCCTCTGTGGCGCTCAGCAACTGCGATGGGCTGGCTGGTCTGATCCGGATGGAGGAGGAGGAGTTCTTCATCGAACCCTTGGAGAAGGGGCTGGCGGCGCAGGAGGCTGAGCAAGGCCGTGTGCATGTGGTGTATCGCCGGCCACCCACGTCCCCTCCTCTCGGGGGGCCACAGGCCCTGGACACAGGGGCCTCCCTGGACAGCCTGGACAGCCTCAGCCGCGCCCTGGGCGTCCTAGAGGAGCACGCCAACAGCTCGAGGCGGAGGGCACGCAGGCATGCTGCGGACGATGACTACAACATCGAGGTCCTGCTGGGCGTGGATGACTCTGTGGTGCAGTTCCACGGGAAGGAGCACGTACAGAAGTACCTGCTGACACTCATGAACATTGTCAATGAAATCTACCATGACGAGTCCTTGGGTGCCCACATCAACGTGGTCCTGGTGCGGATCATCCTCCTGAGCTATGGAAAGTCCATGAGCCTCATCGAGATCGGGAACCCCTCTCAGAGCCTGGAGAATGTCTGCCGCTGGGCCTACCTCCAGCAGAAGCCAGACACGGGCCACGATGAATACCACGATCACGCCATCTTCCTCACACGGCAGGACTTTGGGCCTTCCGGCATGCAAGGCTATGCTCCTGTCACCGGCATGTGCCATCCGGTCCGCAGCTGCACCCTGAACCATGAGGACGGCTTCTCCTCAGCGTTTGTGGTGGCCCATGAGACTGGCCACGTGCTGGGCATGGAGCACGACGGGCAGGGCAACCGCTGTGGCGACGAGGTGCGGCTGGGCAGCATCATGGCGCCCCTGGTGCAGGCCGCCTTCCACCGCTTCCACTGGTCCCGCTGCAGCCAGCAGGAGCTGAGCCGCTACCTGCACTCCTATGACTGCCTGCTGGATGACCCCTTCGCCCACGACTGGCCGGCGCTGCCCCAGCTCCCGGGACTGCACTACTCCATGAACGAGCAATGCCGCTTTGACTTCGGCCTGGGCTACATGATGTGCACGGCGTTCCGGACCTTTGACCCCTGCAAGCAGCTGTGGTGCAGCCATCCTGACAACCCCTACTTTTGCAAGACCAAGAAGGGGCCCCCCTTGGACGGGACTATGTGTGCACCTGGCAAGCATTGTTTTAAAGGACACTGCATCTGGCTGACACCTGACATCCTCAAACGGGACGGCAGCTGGGGCGCTTGGAGTCCGTTTGGCTCCTGCTCACGTACCTGTGGCACGGGCGTGAAGTTCAGGACCCGCCAGTGTGACAACCCACACCCGGCCAACGGGGGCCGCACCTGCTCGGGCCTTGCCTACGACTTCCAGCTCTGCAGCCGCCAGGACTGCCCCGACTCCCTGGCTGACTTCCGCGAGGAGCAGTGCCGCCAGTGGGACCTGTACTTCGAGCACGGCGACGCCCAGCACCACTGGCTGCCCCACGAGCACCGGGATGCCAAGGAGAGATGCCACCTGTACTGCGAGTCCAGGGAGACCGGGGAGGTGGTGTCCATGAAGCGCATGGTGCATGACGGGACGCGCTGCTCCTACAAGGACGCCTTCAGCCTCTGTGTGCGCGGGGACTGCAGGAAGGTGGGCTGTGACGGTGTGATCGGCTCCAGCAAGCAGGAAGACAAGTGTGGCGTGTGCGGAGGGGACAACAGCCACTGCAAAGTGGTCAAGGGCACGTTCACACGGTCACCCAAGAAGCATGGTTACATCAAGATGTTTGAGATCCCTGCAGGAGCCAGACACCTGCTCATTCAGGAGGTAGACGCCACCAGCCACCATCTGGCCGTCAAGAACCTGGAGACAGGCAAGTTCATCTTAAATGAAGAGAATGACGTGGATGCCAGTTCCAAAACCTTCATTGCCATGGGCGTGGAGTGGGAGTACAGAGACGAGGACGGCCGGGAGACGCTGCAGACCATGGGCCCCCTCCACGGCACCATCACCGTTCTGGTCATCCCGGTGGGAGACACCCGGGTCTCACTGACGTACAAATACATGATCCATGAGGACTCACTGAATGTCGACGACAACAACGTCCTGGAAGAGGACTCTGTGGTCTACGAGTGGGCCCTGAAGAAGTGGTCTCCGTGCTCCAAGCCCTGTGGCGGAGGGTCCCAGTTCACCAAGTATGGCTGCCGCCGGAGGCTGGACCACAAGATGGTACACCGTGGCTTCTGTGCCGCCCTCTCGAAGCCCAAAGCCATCCGCAGAGCGTGCAACCCACAGGAATGCTCCCAGCCAGTGTGGGTCACAGGCGAATGGGAGCCATGTAGCCAGACCTGTGGGCGGACAGGCATGCAGGTGCGCTCCGTGCGCTGCATTCAGCCGCTACACGACAACACCACCCGCTCCGTGCACGCCAAGCACTGCAATGACGCCCGGCCCGAGAGCCGCCGGGCCTGCAGCCGCGAGCTCTGCCCTGGTCGTTGGCGAGCCGGGCCCTGGTCCCAGTGCTCAGTAACCTGTGGCAACGGCACCCAGGAGCGGCCAGTGCTCTGCCGCACCGCGGACGACAGCTTCGGCATCTGCCAGGAGGAGCGTCCTGAGACAGCGAGGACCTGCAGGCTTGGCCCCTGTCCCCGAAACATCTCAGATCCCTCCAAGAAGAGCTACGTAGTTCAGTGGCTGTCCCGCCCGGACCCCGACTCGCCCATCCGGAAGATCTCGTCAAAGGGCCACTGCCAAGGCGACAAGTCAATATTCTGTAGGATGGAAGTCTTGTCCCGCTATTGCTCCATCCCAGGCTACAACAAGCTGTGCTGCAAGTCCTGTAACCTGTACAACAACCTCACCAACGTGGAGGGCAGGATAGAGCCACCGCCTGGGAAGCACAACGACATTGACGTGTTCATGCCTACCCTCCCAGTGCCCACTGTAGCCATGGAGGTGCGGCCATCACCAAGCACCCCCCTGGAGGTCCCTCTCAATGCCTCCAGCACCAATGCCACAGAGGATCACCCAGAAACCAATGCCGTAGATGAACCCTACAAAATCCATGGCCTGGAAGATGAAGTCCAGCCACCCAACCTAATCCCTCGACGACCGAGCCCCTATGAAAAGACCAGAAACCAAAGAATCCAAGAGCTCATTGATGAGATGCGGAAGAAAGAGATGCTCGGAAAGTTCTAA
ORF Protein Sequence MDPPAGAARRLLCPALLLLLLLLPPPLLPPPPPPANARLAAAADPPGGPLGHGAERILAVPVRTDAQGRLVSHVVSAATSRAGVRARRAAPVRTPSFPGGNEEEPGSHLFYNVTVFGRDLHLRLRPNARLVAPGATMEWQGEKGTTRVEPLLGSCLYVGDVAGLAEASSVALSNCDGLAGLIRMEEEEFFIEPLEKGLAAQEAEQGRVHVVYRRPPTSPPLGGPQALDTGASLDSLDSLSRALGVLEEHANSSRRRARRHAADDDYNIEVLLGVDDSVVQFHGKEHVQKYLLTLMNIVNEIYHDESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYLQQKPDTGHDEYHDHAIFLTRQDFGPSGMQGYAPVTGMCHPVRSCTLNHEDGFSSAFVVAHETGHVLGMEHDGQGNRCGDEVRLGSIMAPLVQAAFHRFHWSRCSQQELSRYLHSYDCLLDDPFAHDWPALPQLPGLHYSMNEQCRFDFGLGYMMCTAFRTFDPCKQLWCSHPDNPYFCKTKKGPPLDGTMCAPGKHCFKGHCIWLTPDILKRDGSWGAWSPFGSCSRTCGTGVKFRTRQCDNPHPANGGRTCSGLAYDFQLCSRQDCPDSLADFREEQCRQWDLYFEHGDAQHHWLPHEHRDAKERCHLYCESRETGEVVSMKRMVHDGTRCSYKDAFSLCVRGDCRKVGCDGVIGSSKQEDKCGVCGGDNSHCKVVKGTFTRSPKKHGYIKMFEIPAGARHLLIQEVDATSHHLAVKNLETGKFILNEENDVDASSKTFIAMGVEWEYRDEDGRETLQTMGPLHGTITVLVIPVGDTRVSLTYKYMIHEDSLNVDDNNVLEEDSVVYEWALKKWSPCSKPCGGGSQFTKYGCRRRLDHKMVHRGFCAALSKPKAIRRACNPQECSQPVWVTGEWEPCSQTCGRTGMQVRSVRCIQPLHDNTTRSVHAKHCNDARPESRRACSRELCPGRWRAGPWSQCSVTCGNGTQERPVLCRTADDSFGICQEERPETARTCRLGPCPRNISDPSKKSYVVQWLSRPDPDSPIRKISSKGHCQGDKSIFCRMEVLSRYCSIPGYNKLCCKSCNLYNNLTNVEGRIEPPPGKHNDIDVFMPTLPVPTVAMEVRPSPSTPLEVPLNASSTNATEDHPETNAVDEPYKIHGLEDEVQPPNLIPRRPSPYEKTRNQRIQELIDEMRKKEMLGKF

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-SE0569-Ab Anti-ATS2/ ADAMTS2/ ADAM-TS2 functional antibody
    Target Antigen GM-Tg-g-SE0569-Ag ADAMTS2 protein
    ORF Viral Vector pGMAD000269 Human ADAMTS2 Adenovirus plasmid
    ORF Viral Vector vGMAD000269 Human ADAMTS2 Adenovirus particle


    Target information

    Target ID GM-SE0569
    Target Name ADAMTS2
    Gene ID 9509, 216725, 713532, 287899, 101096945, 481453, 282401, 100630632
    Gene Symbol and Synonyms ADAM-TS 2,ADAM-TS2,ADAMTS-2,ADAMTS-3,ADAMTS2,EDSDERMS,NPI,PC I-NP,PCI-NP,PCINP,PCPNI,PNPI,RGD1565950
    Uniprot Accession O95450
    Uniprot Entry Name ATS2_HUMAN
    Protein Sub-location Secreted Protein/Potential Cytokines
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000087116
    Target Classification Not Available

    This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The encoded preproprotein is proteolytically processed to generate the mature procollagen N-proteinase. This proteinase excises the N-propeptide of the fibrillar procollagens types I-III and type V. Mutations in this gene cause Ehlers-Danlos syndrome type VIIC, a recessively inherited connective-tissue disorder. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Feb 2016]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.